Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.
Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic kaposi sarcoma / F. Ingegnoli, A. Tourlaki, R. Gualtierotti. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - 34:2(2014 Feb), pp. 159-161. [10.1007/s40261-013-0159-9]
Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic kaposi sarcoma
F. IngegnoliPrimo
;A. TourlakiSecondo
;R. GualtierottiUltimo
2014
Abstract
Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
